Performance analysis of Acrivon Therapeutics (ACRV)
Annual Return
Over the past 3 years, ACRV has had an average annual return of -48.67%, underperforming the benchmark SPY, which returned +19.31% annual.
Since Nov 15, 2022, ACRV has had an average annual return of -45.86%, underperforming the benchmark SPY, which returned +20.02% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -27.76% | -59.98% | +22.35% | -57.29% | -30.77% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -25.69% | -15.71% | -7.94% | +33.17% | -13.49% | +11.23% | -2.24% | -27.76% | |||||
| 2025 | +0.83% | -12.53% | -61.77% | -31.07% | -24.97% | +13.31% | +7.55% | +4.68% | +35.16% | +9.93% | +18.56% | +2.12% | -59.98% |
| 2024 | -25.80% | +33.14% | +47.11% | +27.14% | -15.08% | -24.85% | +44.46% | +13.24% | -26.23% | +14.29% | -5.26% | -20.57% | +22.35% |
| 2023 | +40.63% | +25.43% | -37.55% | -2.99% | -4.31% | +10.02% | -4.01% | -5.79% | -18.43% | -45.19% | -22.71% | +21.49% | -57.29% |
| 2022 | -22.78% | -10.35% | -30.77% |
Drawdown analysis of Acrivon Therapeutics (ACRV)
The maximum drawdown for the ACRV was -95.47%, occurring on May 30, 2025. This drawdown has not yet recovered.
The current ACRV drawdown is -92.50%.
Since Nov 15, 2022 ACRV has experienced the following drawdowns:
- 50% or more: 1 time
- 40% or more: 1 time
- 30% or more: 2 times
- 20% or more: 2 times
- 10% or more: 2 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -95.47% | Feb 14, 2023 | 574 | May 30, 2025 | Ongoing | Ongoing | Ongoing |
| -32.24% | Nov 16, 2022 | 25 | Dec 22, 2022 | 27 | Feb 2, 2023 | 52 |
| -2.62% | Feb 8, 2023 | 2 | Feb 10, 2023 | 1 | Feb 13, 2023 | 3 |